28
Views
16
CrossRef citations to date
0
Altmetric
Original Article

Does Tirapazamine (SR-4233) Have Any Cytotoxic or Sensitizing Effect on Three Human Tumour Cell Lines at Clinically Relevant Partial Oxygen Pressure?

&
Pages 211-216 | Received 01 Jun 1994, Accepted 26 Sep 1994, Published online: 03 Jul 2009

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (2)

William A. Denny. (2004) Tumor-activated Prodrugs—A New Approach to Cancer Therapy. Cancer Investigation 22:4, pages 604-619.
Read now
William A Denny & William R Wilson. (2000) Tirapazamine: a bioreductive anticancer drug that exploits tumour hypoxia. Expert Opinion on Investigational Drugs 9:12, pages 2889-2901.
Read now

Articles from other publishers (14)

Nuria Vilaplana-Lopera, Maxym Besh & Eui Jung Moon. (2021) Targeting Hypoxia: Revival of Old Remedies. Biomolecules 11:11, pages 1604.
Crossref
Ishna N. Mistry, Matthew Thomas, Ewen D.D. Calder, Stuart J. Conway & Ester M. Hammond. (2017) Clinical Advances of Hypoxia-Activated Prodrugs in Combination With Radiation Therapy. International Journal of Radiation Oncology*Biology*Physics 98:5, pages 1183-1196.
Crossref
Nabila Kazmi, M.A. Hossain & Roger M. Phillips. (2012) A Hybrid Cellular Automaton Model of Solid Tumor Growth and Bioreductive Drug Transport. IEEE/ACM Transactions on Computational Biology and Bioinformatics 9:6, pages 1595-1606.
Crossref
N. Kazmi, M.A. Hossain, R.M. Phillips, M.A. Al-Mamun & R. Bass. (2012) Avascular tumour growth dynamics and the constraints of protein binding for drug transportation. Journal of Theoretical Biology 313, pages 142-152.
Crossref
N. Kazmi, M. A. Hossain & R. Phillips. (2011) A hybrid cellular automaton model of bioreductive drug transportation with protein binding. A hybrid cellular automaton model of bioreductive drug transportation with protein binding.
Bo Hong, Vivian W. Y. Lui, Edwin P. Hui, Margaret H. L. Ng, Suk-Hang Cheng, Fion L. Sung, Chi-Man Tsang, Sai-Wah Tsao & Anthony Tak-Cheung Chan. (2009) Hypoxia-targeting by tirapazamine (TPZ) induces preferential growth inhibition of nasopharyngeal carcinoma cells with Chk1/2 activation. Investigational New Drugs 29:3, pages 401-410.
Crossref
N. Kazmi, M. A. Hossain & R. M. Phillips. 2011. 5th International Conference on Practical Applications of Computational Biology & Bioinformatics (PACBB 2011). 5th International Conference on Practical Applications of Computational Biology & Bioinformatics (PACBB 2011) 125 132 .
Tanguy Y Seiwert, Joseph K Salama & Everett E Vokes. (2007) The concurrent chemoradiation paradigm—general principles. Nature Clinical Practice Oncology 4:2, pages 86-100.
Crossref
Rachel L. Cowen, Kaye J. Williams, Edwin C. Chinje, Mohammed Jaffar, Freda C. D. Sheppard, Brian A. Telfer, Natasha S. Wind & Ian J. Stratford. (2004) Hypoxia Targeted Gene Therapy to Increase the Efficacy of Tirapazamine as an Adjuvant to Radiotherapy. Cancer Research 64:4, pages 1396-1402.
Crossref
Donald J. AbrahamWilliam A. Denny. 2003. Burger's Medicinal Chemistry and Drug Discovery. Burger's Medicinal Chemistry and Drug Discovery 51 105 .
E. Lartigau, S. Stern & M. Guichard. (2000) Survie in vitro « oxygène dépendantede deux lignées humaines après irradiation associée à la tirapazamine (SR-4233) et au cisplatine. Cancer/Radiothérapie 4:3, pages 217-222.
Crossref
Eric Lartigau & Marcelle Guichard. 1999. Antiangiogenic Agents in Cancer Therapy. Antiangiogenic Agents in Cancer Therapy 23 35 .
E Lartigau. (1998) Radiosensibilisateurs des cellules hypoxiques : passé, présent et avenir. Cancer/Radiothérapie 2:6, pages 775-780.
Crossref
E Lartigau, A Lusinchi, P Weeger, P Wibault, B Luboinski, F Eschwege & M Guichard. (1998) Variations in tumour oxygen tension (pO2) during accelerated radiotherapy of head and neck carcinoma. European Journal of Cancer 34:6, pages 856-861.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.